NCT05950308View on ClinicalTrials.gov

Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies

CompletedOBSERVATIONAL
Enrollment

61

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

July 14, 2022

Study Completion Date

July 14, 2022

Conditions
Multiple Sclerosis
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY